Is BRCA2 p.Asp3095Glu (c.9285C>A) pathogenic?

BRCA2 p.Asp3095Glu (c.9285C>A) is classified Pathogenic/Likely pathogenic in BRCA2 (ClinVar, Multiple submitters, 5 submitters; last evaluated 2023-12-21). AlphaMissense: likely pathogenic (0.8367); Absent from gnomAD v4.1; Associated with hereditary neoplastic syndrome.

What condition is associated with BRCA2 p.Asp3095Glu (c.9285C>A)?

BRCA2 p.Asp3095Glu (c.9285C>A) is associated with hereditary neoplastic syndrome, hereditary breast ovarian cancer syndrome, breast-ovarian cancer, familial, susceptibility to, 2 (ClinVar).

How common is BRCA2 p.Asp3095Glu (c.9285C>A) in the general population?

BRCA2 p.Asp3095Glu (c.9285C>A) is absent from gnomAD v4.1 (gnomAD).

What do computational predictors say about BRCA2 p.Asp3095Glu (c.9285C>A)?

AlphaMissense predicts likely pathogenic (score 0.8367) — an in-silico prediction, not a clinical call.

BRCA2 p.Asp3095Glu

c.9285C>A · rs80359198 · VCV252859

Pathogenic/Likely pathogenic Multiple submitters

Classification

Pathogenic/Likely pathogenic

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 5 submitters

AlphaMissense

likely pathogenic

0.8367 · ACMG-weighted

gnomAD v4.1

Absent

absent from gnomAD v4.1

Missense predictors

2/2 damaging

AlphaMissense, REVEL

Conditions

hereditary neoplastic syndrome

Computational evidence

Protein change
AlphaMissense	0.8367	likely pathogenic ✓ concordant with ClinVar · top 3% in BRCA2
REVEL	0.691	pathogenic-leaning
⇒ AlphaMissense and REVEL both call this damaging.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP -1.2	GERP -4.9, phastCons 0.001
Regional constraint	o/e 0.87	unconstrained · MANE · 35 kb · p 0.00024 · regional, not allelic
Overall
CADD	15.84	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Cancer therapy — CIViC

Disease	Therapies	Level	Significance
Breast Cancer		C	Predisposition
		D	Loss of Function

Variant & gene context

Gene: BRCA2
Protein: p.Asp3095Glu
Coding: c.9285C>A
MANE Select: NM_000059
dbSNP: rs80359198
Type: single nucleotide variant
Location: chr13:32394717 (GRCh38)
Gene constraint: LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Residue 3095: a UniProt-annotated variant site (in bc; uncertain significance; reduced homology-directed repair activity)

Full BRCA2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary neoplastic syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary breast ovarian cancer syndrome breast-ovarian cancer, familial, susceptibility to, 2 hereditary breast carcinoma

Similar variants

BRCA2 p.Asp3095= Likely benign ★★★ same residue
BRCA2 p.Asp3095Gly Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Asp3095Val Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Asp3095Ala Uncertain significance ★ ⚠ same residue
BRCA2 c.316+1G>T Pathogenic ★★★ same condition
BRCA2 c.316+2T>C Pathogenic ★★★ same condition
BRCA2 c.316+5G>A Pathogenic ★★★ same condition
BRCA2 c.316+5G>C Pathogenic ★★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-asp3095glu (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown